BackAtara Biotherapeutics Overview

Atara Biotherapeutics Receivables

Atara Biotherapeutics's receivables is $320K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$318000.00

Peer trimmed avg / median

Loading

Atara Biotherapeutics Receivables History

Loading

Atara Biotherapeutics vs. peers: Receivables Comparison

Loading

Atara Biotherapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Atara Biotherapeutics (ATRA) FAQ

Atara Biotherapeutics (ATRA) currently reports a receivables of $320K as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Atara Biotherapeutics's receivables history and peer comparisons.

Atara Biotherapeutics's receivables changed from $0 to $320K (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Atara Biotherapeutics reported $320K in receivables as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $320K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Atara Biotherapeutics, and consider following ATRA for alerts when major investors trade the stock.

Atara Biotherapeutics is classified in the Healthcare sector. On receivables, it currently shows $320K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATRA with unrelated industries.